Login

Fang Guo

ORCID: 0000-0001-7088-3978
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5053556866
Research Areas
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Atherosclerosis and Cardiovascular Diseases
  • Liver Disease and Transplantation
  • Lipoproteins and Cardiovascular Health
  • Nuclear Receptors and Signaling
 The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
OPENALEX - Publications 
Zhu Luo Zhijun Huang Feng Sun Fang Guo Yingying Wang and 6 more Sheena Kao Guoping Yang Jie Huang Jiaxin Li Sylvia Zhao Yan‐Ling He

10.1016/j.jacl.2023.04.010 article EN cc-by Journal of clinical lipidology 2023-04-30
 Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response
OPENALEX - Publications 
Shola M. Richards Fang Guo Heng Zou Florian Nigsch Anna Baiges and 24 more Alok S. Pachori Yiming Zhang Sabela Lens Rebecca Pitts Nancy Finkel Joseph Loureiro Dale Mongeon Shenglin Ma Mollie Watkins Florine Polus Agustı́n Albillos Luís Téllez Javier Martínez-González Rafael Bañares Fanny Turón José Ferrusquía‐Acosta Valeria Pérez‐Campuzano Marta Magaz Xavier Forns Michael K. Badman Andreas W. Sailer Chinweike Ukomadu Virginia Hernández–Gea Juan Carlos García‐Pagán

Abstract Background and Aims A reduction in hepatic venous pressure gradient (HVPG) is the most accurate marker for assessing severity of portal hypertension effectiveness intervention treatments. This study aimed to evaluate prognostic potential blood‐based proteomic biomarkers predicting HVPG response amongst cirrhotic patients with due Hepatitis C virus (HCV) had achieved sustained virologic (SVR). Methods The comprised 59 from two cohorts. Patients underwent paired (pretreatment after...

10.1111/liv.15657 article EN cc-by-nc-nd Liver International 2023-07-13
Coming Soon ...